Latest news with #teledermatology
National Post
22-07-2025
- Business
- National Post
MedX Health Corp. Names John Gevisser as Chief Executive Officer
Article content MISSISSAUGA, Ontario — MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Article content Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. Article content Article content As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. Article content 'John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations,' said Mike Druhan, MedX President, Dermatology Services. 'His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.' Article content 'Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,' said John Gevisser. 'As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.' Article content While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. 'The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,' said Ken McKay, Chairman of the Board. Article content About MedX Health Corp. Article content MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy ® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Article content Article content Article content Article content
Yahoo
22-07-2025
- Business
- Yahoo
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MISSISSAUGA, Ontario, July 22, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. "John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations," said Mike Druhan, MedX President, Dermatology Services. "His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success." "Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism," said John Gevisser. "As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance." While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. "The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time," said Ken McKay, Chairman of the Board.
Globe and Mail
22-07-2025
- Business
- Globe and Mail
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. 'John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations,' said Mike Druhan, MedX President, Dermatology Services. 'His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.' 'Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,' said John Gevisser. 'As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.' While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. 'The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,' said Ken McKay, Chairman of the Board. About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy ® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit:
National Post
21-05-2025
- Business
- National Post
MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy
Article content MISSISSAUGA, Ontario — MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed Biomedical, a MedX commercial partner in Italy, and Medispa, a leading Italian healthcare company delivering innovative digital solutions for prevention, wellness, and healthcare. Article content Article content This new partnership will facilitate the deployment of MedX's proprietary SIAscope on DermSecure® platform across Medispa's extensive network of pharmacies, medical centers, and wellness facilities, increasing patient access to advanced skin screening and preventive care. Article content 'We are pleased to support our partners Vitamed Biomedical and Medispa in bringing our SIAscope on DermSecure® system to a broader patient base in Italy,' said Mike Druhan, President of Dermatological Services at MedX Health Corp. 'This collaboration is an important milestone in our international expansion strategy and underscores our commitment to enabling early detection of melanoma by a dermatologist through accessible, non-invasive teledermatology.' Article content The SIAscope on DermSecure® system enables rapid, non-invasive imaging of suspicious skin lesions, which are securely transmitted for dermatologist review often within 72 hours dramatically accelerating diagnosis while reducing unnecessary referrals and wait times. The solution has been cleared for clinical use across multiple jurisdictions, including the EU, Canada, the U.S., Australia, and the UK. Article content 'This collaboration with Medispa strengthens our mission to expand the reach of teledermatology in Italy,' said Giuseppe Verderame, CEO of Vitamed Biomedical. 'By integrating MedX's platform into high-traffic and trusted community hubs like pharmacies and wellness centers, we are improving accessibility and empowering individuals with better tools for early skin cancer detection.' Article content Andrea Prina, CEO of Medispa, added: 'This partnership perfectly aligns with Medispa's vision of innovating healthcare delivery through digital technology. By offering MedX's solution through our network, we're providing citizens with fast, reliable access to dermatological screening and reinforcing our commitment to prevention-first health services.' Article content Italy represents a key European growth market for MedX Health, where demand for accessible, specialist-level dermatological screening continues to grow particularly in light of increased awareness of skin cancer risks associated with aging populations and sun exposure. Article content About Vitamed Biomedical Article content Vitamed Biomedical is a provider of advanced medical technologies and a commercial partner of MedX in Italy. The company focuses on distributing innovative healthcare solutions that support early diagnosis and patient-centered care across Italy's public and private healthcare sectors. Article content About Medispa Article content Medispa is an Italian company specializing in digital innovation for prevention and wellness services. With a strong presence in pharmacies, medical clinics, and wellness centers, Medispa is dedicated to delivering integrated, forward-thinking health services for the modern consumer. Article content About MedX Health Corp. Article content MedX Health Corp., headquartered in Ontario, Canada, is a leading developer of non-invasive skin analysis and teledermatology solutions. Its SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free imaging of skin lesions for rapid remote dermatologist assessment. MedX products are cleared for use in Canada, the United States, Europe, Australia, and several other markets. Visit: Article content Article content Article content Article content Article content Contacts Article content Article content Article content
National Post
15-05-2025
- Health
- National Post
MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSXV: MDX), the global leader in teledermatology solutions, is pleased to announce the signing of a commercial contract with Health Partners Group Ltd (' HPG ' or ' Health Partners Group '), the United Kingdom's largest occupational health services provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure® skin cancer screening platform. Article content Article content Following the pilot's success (11% of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure® skin cancer screening platform will be rolled out to Health Partners' clients across the UK and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy. Article content 'We are thrilled to deepen our relationship with Health Partners through this commercial agreement,' said Mike Druhan, President of Dermatological Services at MedX. 'This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast-track to a Dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace.' Article content With three million client employees served and 650+ corporate, government, and insurance clients, Health Partners Group is now poised to offer scalable, remote skin cancer screening as a standard part of their client employee health services. Article content 'The pilot validated the accuracy, speed, and accessibility of MedX's technology,' said Andrew Noble, CEO of Health Partners Group. 'Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include Skin Cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under 3 days from the current NHS wait time of between 5-9 months and helping safeguard the health of the UK's workforce.' Article content Skin cancer is among the most common forms of cancer in the UK, with over 220,000 cases diagnosed annually. According to the UK Cancer Alliance, outdoor workers face a 60% higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early and late-stage diagnoses. Article content The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when healthcare systems face growing demand and staffing pressures. Article content About Health Partners Group Ltd. Health Partners Group is the UK's leading occupational health and primary care provider, supporting corporate, government, insurance, and individual clients across the UK and Republic of Ireland. With over 1,300 staff and a robust technology platform, Health Partners Group delivers personalized and scalable health solutions. Visit: Article content About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. Visit: Article content Article content Article content Article content Article content Contacts Article content Article content Article content
